<DOC>
	<DOCNO>NCT00788931</DOCNO>
	<brief_summary>The primary purpose study identify maximum tolerate dose ( MTD ) intravenous oral panobinostat give combination trastuzumab paclitaxel . The study evaluate safety efficacy combination adult female patient HER2+ metastatic breast cancer</brief_summary>
	<brief_title>A Trial l Panobinostat Given Combination With Trastuzumab Paclitaxel Adult Female Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; 18 year old Confirmed HER2+ metastatic breast cancer Prior treatment progression trastuzumab Patients must adequate organ function Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 Patients surgery within last 2 week prior start treatment Patients receive concurrent therapy brain metastasis Impaired heart function clinically significant heart disease Ongoing diarrhea Liver renal disease impair hepatic renal function Concomitant use anticancer therapy certain drug Female patient pregnant breast feed Patients willing use effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>adult-female</keyword>
	<keyword>LBH589</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>panobinostat</keyword>
	<keyword>metastatic breast</keyword>
	<keyword>adult female patient</keyword>
</DOC>